GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InhaleRx Ltd (ASX:IRX) » Definitions » Notes Receivable

InhaleRx (ASX:IRX) Notes Receivable : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Notes Receivable?

InhaleRx's Notes Receivable for the quarter that ended in Dec. 2024 was A$0.00 Mil.


InhaleRx Notes Receivable Historical Data

The historical data trend for InhaleRx's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InhaleRx Notes Receivable Chart

InhaleRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

InhaleRx Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InhaleRx Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


InhaleRx Notes Receivable Related Terms

Thank you for viewing the detailed overview of InhaleRx's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


InhaleRx Business Description

Traded in Other Exchanges
N/A
Address
C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines